TearCare成为第一个也是唯一一个用于改善蒸发性干眼病患者睑板腺功能的MGD治疗

MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to state:

"The Sight Sciences TearCare System is a thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands."

As a result of this expanded indication, TearCare is now the first and only treatment for MGD indicated to improve meibomian gland function in patients suffering from dry eye disease.

Meibomian gland dysfunction is a leading cause of evaporative dry eye disease, affecting millions of patients and significantly impacting visual quality, ocular comfort, and daily vision-related activities. The updated FDA indication reinforces the importance of addressing meibomian gland dysfunction as an underlying cause of dry eye disease while providing eye care providers with a clinically meaningful endpoint focused on gland function.

"This label expansion represents a landmark moment for both the dry eye category and Sight Sciences," said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. "For the first time, eye care providers and patients have a treatment indicated to improve meibomian gland function for evaporative dry eye disease due to MGD. This important milestone reflects our commitment to advancing the science of interventional dry eye disease and providing eye care providers and patients with technologies that address the underlying cause, not just symptoms."

“For chronic, progressive diseases like dry eye disease and glaucoma, meaningful treatment should ultimately be measured by what we can do to preserve or improve physiological function-not simply manage the consequences of disease,” said Neel R. Desai, M.D., Director of Cornea, Cataract, and Refractive Surgery at The Eye Institute of West Florida. “The recognition that TearCare improves meibomian gland function represents an important evolution in dry eye care. It validates the shift toward interventions designed to improve the function disrupted by MGD and raises the bar for what we should expect from treatment.”

Advancing Interventional Dry Eye Care

The TearCare® System is designed to address meibomian gland dysfunction through precisely controlled, targeted thermal energy delivered directly to the eyelids while preserving natural blinking. Its proprietary SmartLids® technology maintains therapeutic heat across the meibomian glands, helping soften obstructive meibum and, when combined with clinician-directed manual expression, effectively clear gland obstructions and improve meibomian gland function.

The updated clearance not only expands TearCare's indication to include improvement of meibomian gland function, but also incorporates optional debridement as part of the TearCare System, further enhancing its comprehensive approach to treating evaporative dry eye disease due to MGD.

For complete indications for use, warnings, precautions, and adverse event information, visit www.sightsciences.com.

About Sight Sciences

Sight Sciences是一家眼科护理技术公司，专注于开发和商业化创新和介入解决方案，旨在改变护理并改善患者生活。Sight Sciences使用微创或非侵入性方法来针对世界上最流行的眼部疾病的根本原因，旨在创建更有效的治疗范式，以加强患者护理并取代传统的过时方法。该公司的OMNI®手术系统和OMNI® Edge手术系统是无植入物的微创青光眼手术技术，在美国用于降低原发性开角型青光眼成人患者的眼内压。OMNI手术系统已获得CE认证，可用于施累姆氏管的导管插入术和经腔粘性扩张术以及小梁网切割术，以降低开角型青光眼成人患者的眼内压。青光眼是世界上不可逆转失明的主要原因。SION®手术系统是一种无刃手动操作器械，用于眼科手术中切除小梁网。该公司的TearCare®系统已在美国获得510（k）批准，用于热激活腺体表达疗法，当与小指腺的手动表达结合使用时，可以改善因小指腺功能障碍（MVD）导致的蒸发性干眼疾病的成年患者的小指腺功能，从而使医生能够清除腺体阻塞，以解决干眼疾病的主要原因。请访问www.sightsciences.com了解更多信息。

Sight Sciences、TearCare和SmartLids是Sight Sciences在美国注册的商标。OMNI、ION和Sight Sciences徽标是Sight Sciences在美国、欧盟和其他地区注册的商标。TruLock是Sight Sciences的商标。

© 2026 Sight Sciences。All rights reserved.

前瞻性陈述

本新闻稿以及公司公开传播的其他声明和信息包含经修订的1933年证券法第27 A条和经修订的1934年证券交易法第21 E条含义内的某些前瞻性陈述。本公司打算将此类前瞻性陈述纳入1995年《私人证券诉讼改革法案》中前瞻性陈述的安全港条款，并纳入本声明以遵守这些安全港条款。本新闻稿中发表的任何非历史事实陈述的声明，包括有关我们的信念和期望的声明，都是前瞻性陈述，应以此进行评估。前瞻性陈述包括但不限于有关扩大适应症的潜在益处和影响的陈述、TearCare在治疗MVD/干眼病中的潜在作用、商业机会、市场采用以及Sight的TearCare计划或目标的陈述。这些陈述通常包括“预期”、“期望”、“建议”、“计划”、“相信”、“意图”、“估计”、“目标”、“项目”、“应该”、“可以”、“会”、“可能”、“将”、“预测”和其他类似表达。我们的这些前瞻性陈述基于我们根据行业经验做出的当前预期、计划和假设，以及我们对历史趋势、当前条件、预期未来发展以及我们认为在当时情况下合适的其他因素的看法。尽管我们相信这些前瞻性陈述是基于做出时的合理假设，但您应该意识到，许多因素可能会影响我们的业务、运营结果和财务状况，包括但不限于我们产品的报销范围或付款决定或报销率的变化;不断变化的竞争格局导致的定价压力或市场份额变化;关税对我们的产品和整个医疗器械行业的影响;以及与我们供应链相关的中断或成本增加，包括由于供应商数量有限而造成的。如果我们的基本假设被证明不正确，实际结果可能与前瞻性陈述中表达的结果存在重大差异。这些陈述并不能保证未来的绩效或结果。这些前瞻性陈述受制于并涉及许多风险、不确定性和假设，包括我们向SEC提交的文件中“风险因素”标题下讨论的风险、不确定性和假设，这些风险、不确定性和假设可能会在后续文件中不时更新，您不应过度依赖这些陈述。这些警告性声明仅于本新闻稿发布之日发布。我们没有义务更新或修改任何前瞻性陈述，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。

投资者联系方式：Philip Taylor Gilmartin Group 415.937.5406 Investor. Relations@www.example.com

媒体联系方式：www.example.com